• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    1/3/24 8:52:12 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 zk2430730.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Seer, Inc.
    (Name of Issuer)
     
    Class A Common Stock, Par Value $0.00001 per Share

    (Title of Class of Securities)
     
    81578P106
    (CUSIP Number)

    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☒ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
     


     
    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,112,235
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,112,235
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,112,235
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    6.44%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 


    Page 2 of 10 Pages

    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Co-Investment SPV I, L.P.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    810,961
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    810,961
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    810,961
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    1.27%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

     
    Page 3 of 10 Pages


    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund G.P. Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 4 of 10 Pages


    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon General Partner Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    Page 5 of 10 Pages

     

    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    Dr. Yair C. Schindel
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    IN
     

    Page 6 of 10 Pages



    Item 1(a)
    Name of Issuer
     
    Seer, Inc. (the “Issuer”).
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    3800 Bridge Parkway, Suite 102, Redwood City, California 94065
     
    Item 2(a)-(b)
    Name of Person Filing; Address of Principal Business Office or, if none, Residence


    1.
    aMoon Growth Fund Limited Partnership (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    2.
    aMoon Co-Investment SPV I, L.P. (“aMoon Co-Investment”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    3.
    aMoon Growth Fund G.P. Limited Partnership (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    4.
    aMoon General Partner Ltd. (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    5.
    Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     
    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. 
     
    Item 2(c)
    Citizenship
             
    aMoon is a Cayman Islands exempted limited partnership; aMoon Co-Investment is a Cayman Islands exempted limited partnership; aMoon G.P. is an Israeli limited partnership; aMoon Ltd. is an Israeli company; and Schindel is an Israeli citizen. 
     
    Item 2(d) 
    Title of Class of Securities

    Class A Common Stock, par value $0.00001 per share
     
    Item 2(e)
    CUSIP Number

    81578P106
     
    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    Not applicable.
     
    Item 4
    Ownership

    aMoon Growth Fund Limited Partnership


    (a)
    Amount beneficially owned:  4,112,235 shares of Class A Common Stock.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.

    Page 7 of 10 Pages


    (b)
    Percent of Class: 6.44%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,112,235 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,112,235 shares of Class A Common Stock

    aMoon Co-Investment SPV I, L.P.


    (a)
    Amount beneficially owned: 810,961 shares of Class A Common Stock.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 1.27%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 810,961 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 810,961 shares of Class A Common Stock

    aMoon Growth Fund G.P. Limited Partnership


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  aMoon G.P. is the sole general partner of aMoon and aMoon Co-Investment.  By virtue of such relationship, aMoon G.P. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    aMoon General Partner Ltd.


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  aMoon Ltd. is the sole general partner of aMoon G.P.  By virtue of such relationships, aMoon Ltd. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.

    Page 8 of 10 Pages


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    Dr. Yair C. Schindel


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment. Schindel disclaims beneficial ownership of the shares of Class A Common Stock of the Issuer held by aMoon, aMoon Co-Investment, aMoon G.P. and aMoon Ltd., except to the extent of his pecuniary interest therein, if any.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class

    Not applicable.
     
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     
    Not applicable.
     
    Item 8
    Identification and Classification of Members of the Group
     
    Incorporated by reference to Items 2 and 4 of this Schedule 13G.
     
    Item 9
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10
    Certification

    Not applicable.
    Page 9 of 10 Pages

     
    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 3, 2024

      AMOON GROWTH FUND LIMITED PARTNERSHIP
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON CO-INVESTMENT SPV, L.P.
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GENERAL PARTNER LTD.
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    DR. YAIR C. SCHINDEL
     
           

    By:
    /s/ Dr. Yair C. Schindel  

    Page 10 of 10 Pages
    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    5/4/2026$4.00Buy
    Canaccord Genuity
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/21/26 5:12:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:20:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Bazarko Anthony R.

    3 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:19:02 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Seer with a new price target

    Canaccord Genuity initiated coverage of Seer with a rating of Buy and set a new price target of $4.00

    5/4/26 8:35:45 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Files ITC Complaint Against Nanomics

    REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a complaint at the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd. The Brigham and Women's Hospital has joined the ITC complaint as well. The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC

    5/29/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders

    Corrects the Board's Flawed Reasons for Rejecting its Credible, Premium Acquisition Offer in Apparent Breach of its Fiduciary Duty Reaffirms its Fully Financed Proposal to Acquire Seer for $2.40 per Share in Cash – a 42% Premium to the Unaffected Share Price – and a CVR for Stockholders to Receive 80% of the Net Proceeds from the Company's Assets Files Preliminary Proxy Statement to Give Stockholders the Opportunity to Elect Three New Qualified, Independent Directors Who Intend to Advocate for a Strategic Review Process Aimed at Maximizing Value for All Seer Stockholders Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), wh

    5/27/26 4:30:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DFRN14A filed by Seer Inc.

    DFRN14A - Seer, Inc. (0001726445) (Subject)

    6/4/26 5:02:22 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    6/3/26 5:24:15 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    6/3/26 5:22:33 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

    Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer's Proteograph® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced the appointment of Anthony Bazarko as Chief Commercial Officer. Mr. Bazarko brings more than two decades of commercial leadership experience across the life sciences, diagnostics, and biotechnology industries, with a demonstrated track record of driving revenue growth, building high-performing teams, and leading global go-to-market strategies. Mr. Bazarko joins Seer from

    5/4/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

    REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo

    5/13/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report First Quarter 2026 Financial Results on May 13, 2026

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the first quarter 2026 on Wednesday, May 13, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, pr

    4/29/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials